Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients

Journal of the National Cancer Institute

Volumn 86, Issue 20, 1994, Pages 1530-1533

  Lund, Birthe ^a   Hansen, Ole Paaske ^b   Theilade, Karen ^c   Hansen, Mogens ^d   Neijt, Jan P ^e  

^a University of Copenhagen   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d HILLERØD HOSPITAL   (Denmark)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; EDEMA; FEMALE; HEMATURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TUMOR GROWTH;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMAN; INFUSIONS, INTRAVENOUS; MIDDLE AGE; OVARIAN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0028020890     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/86.20.1530     Document Type: Article

References (10)

1. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al: Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 27:1367-1372, 1991
2. Lund B, Krtstjansen PE, Hansen HH: Clinical and preclinical activity of 2', 2'-difluorode- oxycytidine (gemcitabine). Cancer Treat Rev 19:45-55, 1993
3. Markman, M. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO, 1979
4. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cispla- tin. J Clin Oncol 9:389-393, 1991
5. Blackledge G, Lawton F, Redman C, et al: Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. BrJ Cancer 59:650-653, 1989
6. Hansen HH, Eisenhauer EA, Hansen M, et al: New cytostatic drugs in ovarian cancer. Ann Oncol 4 Suppl 4:S63-70, 1993
7. Hoskins PJ, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994
8. Trimble EL, Adams JD, Vena D, et al: Paclitaxel for platinum-refractory ovarian cancer: results from the first 1, 000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11:2405-2410, 1993
9. Pazdur R, Kudelka AP, Kavanagh JJ, et al: The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19:351-386, 1993
10. Morgan-Ihrig C, Lembersky B, Christopherson W, et al: A phase II evaluation of difluoro- deoxy-cytidine (dFdC) in advanced stage refractory ovarian cancer. Proc ASCO 10:196, 1991